

David J Maron

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4726077/publications.pdf>

Version: 2024-02-01

89
papers

11,015
citations

145106

33
h-index

60403

85
g-index

91
all docs

91
docs citations

91
times ranked

8874
citing authors

#	ARTICLE	IF	CITATIONS
1	Effects of initial invasive vs. initial conservative treatment strategies on recurrent and total cardiovascular events in the ISCHEMIA trial. <i>European Heart Journal</i> , 2022, 43, 148-149.	1.0	13
2	Cardiac CT angiography in current practice: An American society for preventive cardiology clinical practice statement ^o . <i>American Journal of Preventive Cardiology</i> , 2022, 9, 100318.	1.3	16
3	Causes of cardiovascular and noncardiovascular death in the ISCHEMIA trial. <i>American Heart Journal</i> , 2022, 248, 72-83.	1.2	15
4	Predictors of Left Main Coronary Artery Disease in the ISCHEMIA Trial. <i>Journal of the American College of Cardiology</i> , 2022, 79, 651-661.	1.2	14
5	Comprehensive Quality-of-Life Outcomes With Invasive Versus Conservative Management of Chronic Coronary Disease in ISCHEMIA. <i>Circulation</i> , 2022, 145, 1294-1307.	1.6	11
6	Outcomes With Intermediate Left Main Disease: Analysis From the ISCHEMIA Trial. <i>Circulation: Cardiovascular Interventions</i> , 2022, 15, CIRCINTERVENTIONS121010925.	1.4	4
7	Timing of statin dose: a systematic review and meta-analysis of randomized clinical trials. <i>European Journal of Preventive Cardiology</i> , 2022, 29, e319-e322.	0.8	2
8	Clinical and Quality-of-Life Outcomes Following Invasive vs Conservative Treatment of Patients With Chronic Coronary Disease Across the Spectrum of Kidney Function. <i>JAMA Cardiology</i> , 2022, 7, 825.	3.0	2
9	Myocardial Infarction in the ISCHEMIA Trial. <i>Circulation</i> , 2021, 143, 790-804.	1.6	81
10	CT Angiography Followed by Invasive Angiography in Patients With Moderate or Severe Ischemia-Insights From the ISCHEMIA Trial. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 1384-1393.	2.3	37
11	Digital Health Interventions for Cardiac Rehabilitation: Systematic Literature Review. <i>Journal of Medical Internet Research</i> , 2021, 23, e18773.	2.1	77
12	Response by Bangalore et al to Letter Regarding Article, "Routine Revascularization Versus Initial Medical Therapy for Stable Ischemic Heart Disease: A Systematic Review and Meta-Analysis of Randomized Trials". <i>Circulation</i> , 2021, 143, e809-e810.	1.6	1
13	Response by Lopes et al to Letter Regarding Article, "Initial Invasive Versus Conservative Management of Stable Ischemic Heart Disease Patients With a History of Heart Failure or Left Ventricular Dysfunction: Insights From the ISCHEMIA Trial". <i>Circulation</i> , 2021, 143, e961-e962.	1.6	0
14	Automated coronary calcium scoring using deep learning with multicenter external validation. <i>Npj Digital Medicine</i> , 2021, 4, 88.	5.7	59
15	Kidney Transplant List Status and Outcomes in the ISCHEMIA-CKD Trial. <i>Journal of the American College of Cardiology</i> , 2021, 78, 348-361.	1.2	32
16	Response by Chaitman et al to Letter Regarding Article, "Myocardial Infarction in the ISCHEMIA Trial: Impact of Different Definitions on Incidence, Prognosis, and Treatment Comparisons". <i>Circulation</i> , 2021, 144, e14-e15.	1.6	4
17	Disparity in the Setting of Incident Heart Failure Diagnosis. <i>Circulation: Heart Failure</i> , 2021, 14, e008538.	1.6	28
18	Natural History of Patients With Ischemia and No Obstructive Coronary Artery Disease. <i>Circulation</i> , 2021, 144, 1008-1023.	1.6	56

#	ARTICLE	IF	CITATIONS
19	Predictors of Outcome in the ISCHEMIA-CKD Trial: Anatomy versus Ischemia. <i>American Heart Journal</i> , 2021, 243, 187-200.	1.2	4
20	Outcomes in the ISCHEMIA Trial Based on Coronary Artery Disease and Ischemia Severity. <i>Circulation</i> , 2021, 144, 1024-1038.	1.6	140
21	Outcomes of Participants With Diabetes in the ISCHEMIA Trials. <i>Circulation</i> , 2021, 144, 1380-1395.	1.6	24
22	Comparison of Days Alive Out of Hospital With Initial Invasive vs Conservative Management. <i>JAMA Cardiology</i> , 2021, 6, 1023.	3.0	10
23	The Glass Is at Least Half Full. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 2350-2352.	1.1	1
24	Time to Relax the 40-Year Age Threshold for Pharmacologic Cholesterol Lowering. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1965-1967.	1.2	3
25	Abstract 10329: Health Status Outcomes of Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting in Stable Coronary Disease: Secondary Analysis of the ISCHEMIA Trial. <i>Circulation</i> , 2021, 144, .	1.6	0
26	Cardiorespiratory Fitness, Body Mass Index, and Markers of Insulin Resistance in Apparently Healthy Women and Men. <i>American Journal of Medicine</i> , 2020, 133, 825-830.e2.	0.6	14
27	Primary Prevention Trial Designs Using Coronary Imaging. <i>JACC: Cardiovascular Imaging</i> , 2020, 14, 1454-1465.	2.3	22
28	Initial Invasive Versus Conservative Management of Stable Ischemic Heart Disease in Patients With a History of Heart Failure or Left Ventricular Dysfunction. <i>Circulation</i> , 2020, 142, 1725-1735.	1.6	77
29	Risk Prediction Tool for Assessing the Probability of Death or Myocardial Infarction in Patients With Stable Coronary Artery Disease. <i>American Journal of Cardiology</i> , 2020, 130, 1-6.	0.7	2
30	The Project Baseline Health Study: a step towards a broader mission to map human health. <i>Npj Digital Medicine</i> , 2020, 3, 84.	5.7	38
31	Initial Invasive or Conservative Strategy for Stable Coronary Disease. <i>New England Journal of Medicine</i> , 2020, 382, 1395-1407.	13.9	1,508
32	Management of Coronary Disease in Patients with Advanced Kidney Disease. <i>New England Journal of Medicine</i> , 2020, 382, 1608-1618.	13.9	310
33	Health-Status Outcomes with Invasive or Conservative Care in Coronary Disease. <i>New England Journal of Medicine</i> , 2020, 382, 1408-1419.	13.9	287
34	Health Status after Invasive or Conservative Care in Coronary and Advanced Kidney Disease. <i>New England Journal of Medicine</i> , 2020, 382, 1619-1628.	13.9	56
35	Association of Sex With Severity of Coronary Artery Disease, Ischemia, and Symptom Burden in Patients With Moderate or Severe Ischemia. <i>JAMA Cardiology</i> , 2020, 5, 773.	3.0	101
36	Routine Revascularization Versus Initial Medical Therapy for Stable Ischemic Heart Disease. <i>Circulation</i> , 2020, 142, 841-857.	1.6	118

#	ARTICLE	IF	CITATIONS
37	Coronary artery calcium testing: A call for universal coverage. <i>Preventive Medicine Reports</i> , 2019, 15, 100879.	0.8	15
38	Studies Evaluating Statin Adherence and Outcome Should Adjust for Smoking Persistence and Antiplatelet Treatment Discontinuationâ€™Reply. <i>JAMA Cardiology</i> , 2019, 4, 832.	3.0	0
39	Controversies in Diagnostic Imaging of Patients With Suspected Stable and Acute Chest Pain Syndromes. <i>JACC: Cardiovascular Imaging</i> , 2019, 12, 1254-1278.	2.3	6
40	Preventive Cardiology as a Subspecialty of Cardiovascular Medicine. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1926-1942.	1.2	39
41	The Comparative Effect of Roux-en-Y Gastric Bypass and Sleeve Gastrectomy on 10-Year and Lifetime Atherosclerotic Cardiovascular Disease Risk. <i>Obesity Surgery</i> , 2019, 29, 3111-3117.	1.1	11
42	Lifestyle, Glycosylated Hemoglobin A1c, and Survival Among Patients With Stable Ischemic Heart Disease and Diabetes. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2049-2058.	1.2	24
43	Baseline Characteristics and Risk Profiles of Participants in the ISCHEMIA Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2019, 4, 273.	3.0	100
44	Effect of Coronary Anatomy and Myocardial Ischemia on Long-Term Survival in Patients with Stable Ischemic Heart Disease. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e005079.	0.9	22
45	Association of Statin Adherence With Mortality in Patients With Atherosclerotic Cardiovascular Disease. <i>JAMA Cardiology</i> , 2019, 4, 206.	3.0	216
46	Baseline Predictors of Low-Density Lipoprotein Cholesterol and Systolic Blood Pressure Goal Attainment After 1 Year in the ISCHEMIA Trial. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e006002.	0.9	26
47	Association of Educational Attainment and Cardiovascular Risk in Hispanic Individuals. <i>JAMA Cardiology</i> , 2019, 4, 43.	3.0	5
48	International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial: Rationale and design. <i>American Heart Journal</i> , 2018, 201, 124-135.	1.2	202
49	Dietary Patterns and Long-Term Survival: A Retrospective Study of Healthy Primary Care Patients. <i>American Journal of Medicine</i> , 2018, 131, 48-55.	0.6	25
50	Healthy Behavior, Risk Factor Control, and Survival in the COURAGE Trial. <i>Journal of the American College of Cardiology</i> , 2018, 72, 2297-2305.	1.2	42
51	Planning and Conducting the ISCHEMIA Trial. <i>Circulation</i> , 2018, 138, 1384-1386.	1.6	17
52	ISCHEMIA: Establishing the Primary End Point. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e004791.	0.9	10
53	The Reply. <i>American Journal of Medicine</i> , 2018, 131, e211.	0.6	0
54	Cost-effectiveness of on-pump and off-pump coronary artery bypass grafting for patients with coronary artery disease: Results from the MASS III trial. <i>International Journal of Cardiology</i> , 2018, 273, 63-68.	0.8	5

#	ARTICLE	IF	CITATIONS
55	International Study of Comparative Health Effectiveness with Medical and Invasive Approaches—Chronic Kidney Disease (ISCHEMIA-CKD): Rationale and design. <i>American Heart Journal</i> , 2018, 205, 42-52.	1.2	44
56	Frequency of Statin Use in Patients With Low-Density Lipoprotein Cholesterol \geq 190 mg/dl from the Veterans Affairs Health System. <i>American Journal of Cardiology</i> , 2018, 122, 756-761.	0.7	20
57	ACC/AATS/AHA/ASE/ASNC/SCAI/SCCT/STS 2016 Appropriate Use Criteria for Coronary Revascularization in Patients With Acute Coronary Syndromes. <i>Journal of Nuclear Cardiology</i> , 2017, 24, 439-463.	1.4	55
58	Intensity of Statin Treatment and Mortality—Reply. <i>JAMA Cardiology</i> , 2017, 2, 928.	3.0	2
59	Use of troponin assay 99th percentile as the decision level for myocardial infarction diagnosis. <i>American Heart Journal</i> , 2017, 190, 135-139.	1.2	26
60	ACC/AATS/AHA/ASE/ASNC/SCAI/SCCT/STS 2017 Appropriate Use Criteria for Coronary Revascularization in Patients With Stable Ischemic Heart Disease. <i>Journal of Nuclear Cardiology</i> , 2017, 24, 1759-1792.	1.4	81
61	Using Absolute Event Rates to See What Works in Cardiovascular Medicine. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1376-1378.	1.2	5
62	Preventive Interventions After Coronary Artery Calcium Scanning. <i>JACC: Cardiovascular Imaging</i> , 2017, 10, 843-844.	2.3	2
63	Using Commercial Programs for Lifestyle Intervention. <i>Journal of the American College of Cardiology</i> , 2017, 70, 328-330.	1.2	2
64	Relationship between simple markers of insulin resistance and coronary artery calcification. <i>Journal of Clinical Lipidology</i> , 2017, 11, 1007-1012.	0.6	9
65	Association Between Intensity of Statin Therapy and Mortality in Patients With Atherosclerotic Cardiovascular Disease. <i>JAMA Cardiology</i> , 2017, 2, 47.	3.0	132
66	Risk Estimates for Atherosclerotic Cardiovascular Disease in Adults With Congenital Heart Disease. <i>American Journal of Cardiology</i> , 2017, 119, 112-118.	0.7	54
67	Treatment of Patients With Stable Ischemic Heart Disease—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 1905.	3.8	0
68	Use of high-intensity statins for patients with atherosclerotic cardiovascular disease in the Veterans Affairs Health System: Practice impact of the new cholesterol guidelines. <i>American Heart Journal</i> , 2016, 182, 97-102.	1.2	44
69	Conservative versus invasive stable ischemic heart disease management strategies: what do we plan to learn from the ISCHEMIA trial?. <i>Future Cardiology</i> , 2016, 12, 35-44.	0.5	5
70	Medical Therapy With Versus Without Revascularization in Stable Patients With Moderate and Severe Ischemia. <i>Journal of the American College of Cardiology</i> , 2016, 67, 81-99.	1.2	90
71	Optimal medical therapy with or without percutaneous coronary intervention in women with stable coronary disease: A pre-specified subset analysis of the Clinical Outcomes Utilizing Revascularization and Aggressive druG Evaluation (COURAGE) trial. <i>American Heart Journal</i> , 2016, 173, 108-117.	1.2	30
72	Accelerated atherosclerosis in patients with chronic inflammatory rheumatologic conditions. <i>International Journal of Clinical Rheumatology</i> , 2015, 10, 365-381.	0.3	25

#	ARTICLE	IF	CITATIONS
73	Validation of the Appropriate Use Criteria for Percutaneous Coronary Intervention in Patients With Stable Coronary Artery Disease (from the COURAGE Trial). American Journal of Cardiology, 2015, 116, 167-173.	0.7	15
74	Why Optimal Medical Therapy Should Be a Universal Standard of Care —. Journal of the American College of Cardiology, 2015, 66, 774-776.	1.2	2
75	Primary Prevention of Heart Failure in Older Adults. JACC: Heart Failure, 2015, 3, 529-530.	1.9	2
76	Identification of Emergency Department Patients With Acute Heart Failure at Low Risk for 30-Day Adverse Events. JACC: Heart Failure, 2015, 3, 737-747.	1.9	83
77	Effect of Baseline Exercise Capacity on Outcomes in Patients With Stable Coronary Heart Disease (A) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T	0.7	2
78	Evidence-Based Management of Stable Ischemic Heart Disease. JAMA - Journal of the American Medical Association, 2015, 314, 1917.	3.8	14
79	Predicting Outcome in the COURAGE Trial (Clinical Outcomes Utilizing Revascularization and) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T	1.1	178
80	Trial to Assess Chelation Therapy (TACT) and equipoise: When evidence conflicts with beliefs. American Heart Journal, 2014, 168, 4-5.	1.2	2
81	As REGARDS Treatment Goal Attainment Compared With COURAGE. Journal of the American College of Cardiology, 2014, 63, 1634-1635.	1.2	1
82	Comparative Definitions for Moderate-Severe Ischemia in Stress Nuclear, Echocardiography, and Magnetic Resonance Imaging. JACC: Cardiovascular Imaging, 2014, 7, 593-604.	2.3	168
83	Baseline stress myocardial perfusion imaging results and outcomes in patients with stable ischemic heart disease randomized to optimal medical therapy with or without percutaneous coronary intervention. American Heart Journal, 2012, 164, 243-250.	1.2	175
84	Optimal Medical Therapy With or Without Percutaneous Coronary Intervention to Reduce Ischemic Burden. Circulation, 2008, 117, 1283-1291.	1.6	1,478
85	Response to Letters Regarding Article, "Optimal Medical Therapy With or Without Percutaneous Coronary Intervention to Reduce Ischemic Burden: Results From the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) Trial Nuclear Substudy". Circulation, 2008, 118, .	1.6	1
86	Health-Risk Appraisal With or Without Disease Management for Worksite Cardiovascular Risk Reduction. Journal of Cardiovascular Nursing, 2008, 23, 513-518.	0.6	16
87	Optimal Medical Therapy with or without PCI for Stable Coronary Disease. New England Journal of Medicine, 2007, 356, 1503-1516.	13.9	4,022
88	Flavonoids for reduction of atherosclerotic risk. Current Atherosclerosis Reports, 2004, 6, 73-78.	2.0	92
89	Cholesterol-Lowering Effect of a Theaflavin-Enriched Green Tea Extract. Archives of Internal Medicine, 2003, 163, 1448.	4.3	202